Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT04150913 is registered in ClinicalTrials.gov with Marcela V. Maus, M.D.,Ph.D. as lead sponsor.

NCT NCT04150913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2020
Completion date
October 31, 2024
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine release syndrome, neurotoxicity, neurotoxicity syndromes, non hodgkin lymphoma, refractory non-hodgkin lymphoma, relapsed non hodgkin lymphoma